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Transforming growth factor-b is a central mediator of the malignant phenotype of glioblastoma, the most common and malig-
nant form of intrinsic brain tumours. Transforming growth factor-b promotes invasiveness and angiogenesis, maintains cancer
cell stemness and induces profound immunosuppression in the host. Integrins regulate cellular adhesion and transmit signals
important for cell survival, proliferation, differentiation and motility, and may be involved in the activation of transforming
growth factor-b. We report that avb3, avb5 and avb8 integrins are broadly expressed not only in glioblastoma blood vessels but
also in tumour cells. Exposure to av, b3 or b5 neutralizing antibodies, RNA interference-mediated integrin gene silencing or
pharmacological integrin inhibition using the cyclic RGD peptide EMD 121974 (cilengitide) results in reduced phosphorylation of
Smad2 in most glioma cell lines, including glioma-initiating cell lines and reduced transforming growth factor-b-mediated
reporter gene activity, coinciding with reduced transforming growth factor-b protein levels in the supernatant. Time course
experiments indicated that the loss of transforming growth factor-b bioactivity due to integrin inhibition likely results from two
distinct mechanisms: an early effect on activation of preformed inactive protein, and second, major effect on transforming
growth factor-b gene transcription as confirmed by decreased activity of the transforming growth factor-b gene promoter and
decreased transforming growth factor-b1 and transforming growth factor-b2 messenger RNA expression levels. In vivo, EMD
121974 (cilengitide), which is currently in late clinical development as an antiangiogenic agent in newly diagnosed glioblast-
oma, was a weak antagonist of pSmad2 phosphorylation. These results validate integrin inhibition as a promising strategy not
only to inhibit angiogenesis, but also to block transforming growth factor-b-controlled features of malignancy including inva-
siveness, stemness and immunosuppression in human glioblastoma.
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Introduction
Human glioblastoma is a highly lethal brain tumour that kills
affected patients by local destructive growth. Surgery, radiother-
apy and alkylating agent chemotherapy represent the current
standard of care, which results in a median overall survival of
51 year on a population level (Preusser et al., 2011).
Transforming growth factor (TGF)-b is a master molecule control-
ling migration, invasiveness and angiogenesis in glioblastoma and
induces profound immunosuppression (Wick et al., 2006). More
recently, TGF-b has also been attributed to an important role in
maintaining the population of cells within glioblastomas exhibiting
stem cell–like properties, often (and also herein) referred to as
glioma-initiating cells (Penuelas et al., 2009; Anido et al., 2010).
Rodent glioma models have confirmed TGF-b as an attractive
target for experimental approaches using gene silencing or
small-molecule TGF-b receptor antagonists (Friese et al., 2004;
Uhl et al., 2004; Zhang et al., 2011). Clinical data confirm that
TGF-b/Smad pathway activity confers a poor prognosis to glioma
patients (Bruna et al., 2007), and TGF-b antagonism is currently
explored as a therapeutic strategy in recurrent glioblastoma
(Bogdahn et al., 2011; Azaro et al., 2012). However, although
the important role of TGF-b in glioblastoma and other cancers is
widely accepted, its therapeutic targeting has remained
challenging.
TGF-b is secreted in a latent complex with its processed
propeptide, latency-associated peptide (Annes et al., 2003) in
the small latent complex. Latent TGF-b-binding proteins covalently
bind the small latent complex to form the large latent complex
(Miyazono et al., 1991). Activation of TGF-b necessitates dissocia-
tion from the small latent complex, which involves proteolytic
cascades or cell traction forces (Wipff and Hinz, 2008). Integrins
constitute a large family of cell surface transmembrane molecules
that are composed of an - and a b-subunit. Eighteen -subunits
and b-subunits form 24 different heterodimeric integrin molecules,
which mediate various complex processes including adhesion,
migration and angiogenesis in a cell type– and context-dependent
manner (Desgrosellier and Cheresh, 2010). Importantly, integrins
may also play an important, but complex, role in activating TGF-b
(Sheppard, 2005; Wipff and Hinz, 2008). Diverse integrins,
including all v integrins, interact with the latency-associated
peptide/TGF-b1 portion of the large latent complex via a L-argi-
nine, glycine, and L-aspartic acid (RGD) motif (Ludbrook et al.,
2003; Sheppard, 2005) and vb6 and vb3 may support TGF-b1
activation (Munger et al., 1999; Mu et al., 2002). However, TGF-
b2/latency-associated peptide does not contain an RGD sequence,
and whether TGF-b2 activation depends on other integrin-depen-
dent mechanisms remains unclear (Sheppard, 2005). Additionally,
TGF-b1 transcription and secretion are stimulated through integrin
activation via an Arg-Gly-Asp-Ser (RGDS) peptide in human
mesangial cells (Ortega-Velazquez et al., 2003). Taken together,
these observations prompted us to explore the possibility of down
regulating the TGF-b pathway in glioblastoma by interfering with
the expression or function of specific integrins expressed in these
tumours.
Materials and methods
Cells and reagents
The human malignant glioma cell lines U87MG and T98G were from
the American Type Culture Collection. LN-18, LNT-229 and LN-308
cells were kindly provided by N. de Tribolet (Lausanne, Switzerland).
The generation, characterization and culturing of glioma-initiating cell
lines GS-2, GS-3, GS-5 and GS-9 have been described previously
(Gunther et al., 2008). These cells were maintained as sphere cultures.
Transfected mink lung epithelial cells, a kind gift from D.B. Rifkin (New
York, NY), were maintained in Dulbecco’s modified Eagle’s medium
containing 10% foetal calf serum (Biochrom) supplemented with G418
(800 mg/ml, Biochrom). AccutaseTM was obtained from PAA.
Recombinant human TGF-b1 was purchased from R&D Systems.
Except for immunohistochemistry, the following antibodies were
used for all experiments: rabbit polyclonal antibody to TGF-b2 and
goat polyclonal antibody to actin were obtained from Santa Cruz
Biotechnology. TGF-b1, phospho-Smad2 (Ser465/467) (clone 138D4)
and Smad2 (clone 86F7) antibodies were purchased from Cell
Signaling Technology. Mouse anti-Smad2/3 antibody was from BD
Biosciences. Anti-v antibody (clone 17E6) was obtained from
Merck. The antibodies to vb3 (clone LM609, MAB1976), vb5
(clone P1F6, MAB1961) and to Glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) were from Chemicon. Mouse serum-free hybridoma
supernatant to integrin b8 (Ab14e5), a generous gift from S.L.
Nishimura (San Francisco, CA), was used at a dilution of 1:100 for
flow cytometry. Murine isotype mouse IgG1 from murine myeloma
was purchased from Sigma-Aldrich. The TGF-b receptor I kinase inhi-
bitor SD-208 was kindly provided by Scios Inc. Cilengitide was pro-
vided by Merck (Darmstadt, Germany). For transient transfections,
3  105 glioma cells were seeded in a six-well plate and transfected
with 100 nM of small interfering RNA pools against a specific integrin
or irrelevant scrambled control. For all integrins, two different small
interfering RNA pools were purchased (Dharmacon/Thermo), using
Metafectene Pro (Biontex).
Real-time polymerase chain reaction
Total RNA was prepared using the RNeasy system including DNase
treatment (Qiagen) and transcribed according to standard protocols.
Complementary DNA was prepared using SuperScript RNase
H Reverse Transcriptase (Invitrogen) and random nonamers
(Cell Signaling). For real-time PCR, gene expression was measured in
an ABI Prism 7000 Sequence Detection System (Applied Biosystems)
with SYBR Green Master Mix (Eurogentec) and primers (Sigma-
Aldrich) at optimized concentrations. GAPDH primers have been pre-
viously described (Carraro et al., 2005). The other sequences were as
follows: TGF-b1, forward 50-GCCCTGGACACCAACTATTG-30
[NM_000660.3, nucleotides (nt) 1702–1727], reverse 50-
CGTGTCCAGGCTCCAAATG-30 (NM_000660.3, nt 1851–1869);
TGF-b2, forward 50-AAGCTTACACTGTCCCTGCTGC-30
(NM_003238.1, nt 847–868), reverse 50-TGTGGAGGTGCCAT
CAATACCT-30 (NM_003228.1, nt 934–955); integrin v, forward
50-AAGTAAGCCCAGTTGTATCTCACAA-30 (NM_002210, nt
2529–2554), reverse 50-GGACTCGAGACTCCTCTTATCTCAA-30
(NM_002210, nt 2581–2605); integrin b3, forward 50-CAGATGC
CTGCACCTTTAAGAAA-30 (NM_000212, nt 1912–1934), reverse
50-TCACGGCAGTAACGGTTGC-30 (NM_000212, nt 1990–2008);
integrin b5, forward 50-CTACACGGCACCGAGGTACC-30
(NM_002213, nt 870–889), reverse 50-CGCAATTTGGAAACAACTT
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GTAAC-30 (NM_002213, nt 908–931); integrin b8, forward
50-TGAAAGTCATATCGGATGGCG-30 (NM_002214, nt 1503–1523),
reverse 50-GCACCACTATGCCTGCCAAT-30 (NM_002214, nt 1590–
1609). The conditions were 40 cycles at 95C/15 s and 60C/1 min.
Standard curves were generated for each gene and the amplification
was 90–100% efficient. Relative quantification of gene expression was
determined by comparison of threshold values. All results were nor-
malized to GAPDH and calculated with the CTT method for relative
quantification.
Immunoblot analysis
For the detection of proteins from cell lysates, cells were lysed in
radioimmunoprecipitation assay buffer (10 mM Tris pH 8.0, 150 mM
NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS) supplemented with
1 complete inhibitor mix (Roche Diagnostics) and phosphatase inhi-
bitor cocktails 1 and 2 (Sigma-Aldrich). Serum-free conditioned media
were concentrated with the centriplus centrifugal filter device YM-3
(3000 Da cut-off; Millipore). Protein levels were analysed by immuno-
blot using 20 mg of protein per lane mixed with Laemmli buffer con-
taining b-mercaptoethanol, unless otherwise indicated, with the
respective antibodies used at the concentrations recommended by
the manufacturer. Equal protein loading was ascertained by Ponceau
S staining. Visualization of protein bands was accomplished using
horseradish peroxidise–coupled secondary antibodies (Sigma-Aldrich)
and enhanced chemiluminescence (Perbio).
Flow cytometry
Glioma cells were detached using AccutaseTM (PAA), resuspended in
buffer for flow cytometry (PBS, 2 mM ethylenediaminetetraacetic acid
(EDTA), 0.5% bovine serum albumin) and incubated for 30 min on ice
using the respective antibodies or isotype-matched control antibody.
This was followed by an R-phycoerythrin-conjugated goat anti-mouse
IgG antibody (1:40) labelling step. Fluorescence was detected in a
CyanADP flow cytometer (DakoCytomation). Specific fluorescence
indices were calculated by dividing the mean fluorescence obtained
with the specific antibody by the mean fluorescence obtained with
the control antibody.
TGF-b1/2 enzyme-linked
immunosorbent assay
The cells (2  105/well) were seeded in a six-well plate and exposed
to the control peptide RAD or cilengitide as indicated. Supernatants
were harvested after 48 h. To activate latent TGF-b1/2 to the bioactive
form, hydrochloric acid was added, followed by incubation at room
temperature for 15 min. Acidified samples were neutralized with
sodium hydroxide. Subsequently, the samples were serially diluted
with PBS. TGF-b1 and -b2 concentrations were measured by
Enzyme-linked immunosorbent assay (ELISA) according to the manu-
facturer’s protocol (R&D Systems).
Immunohistochemistry
Gliomas of different World Health Organization (WHO) grades of
malignancy were analysed on a tissue microarray. The tissue microar-
ray was constructed as previously described (Kononen et al., 1998)
and contained 14 grade II, 27 grade III and 26 grade IV primary
gliomas. Two 0.6 mm cores were punched from each of the 67
tumour paraffin blocks. Tissue microarray sections were incubated
according to Ventana automat protocols (Ventana Medical System)
using the following rabbit monoclonal primary antibodies: anti-integrin
pan-v (clone EM01309, 1:10 000), anti-integrin vb3 (clone
EM22703, 1:200), anti-integrin vb5 (clone EM09902, 1:1000), anti-
integrin vb6 (clone EM05201, 1:2000) and anti-integrin vb8 (clone
EM13309, 1:750) as described (Goodman et al., 2012). The immu-
nostaining was performed using anti-rabbit secondary antibodies with
iViewTM or ultraViewTM Amp kits (Ventana). The intensity of integrin
staining for pan-v, vb3, vb5, vb6 and vb8 was scored 0 (nega-
tive), + 1 (weak), + 2 (moderate) and + 3 (strong) in tumour cells as
well as in endothelial cells. Contingency table analysis and Pearson’s
chi-square tests were used for the analysis of the associations between
integrin expression patterns and glioma grade.
Immunofluorescence microscopy
Immunofluorescence studies were carried out on cytospins (5  105
cells/slide). Samples were dried for 30 min and fixed in a 4% buffered
formalin solution for 10 min at room temperature. Subsequently, anti-
body to pSmad2 (Cell Signaling) was applied (overnight at 4C).
Binding specificity was controlled by IgG isotype control (Jackson
Immunoresearch). For visualization, Cy3-conjugated AffiniPure
donkey anti-rabbit IgG (Jackson Immunoresearch) was applied. All
sections were mounted in Vectashield Mounting Media with 4’,6-dia-
midino-2-phenylindole (DAPI).
TGF-b activity assay
Transfected mink lung epithelial cells, stably transfected with a lucifer-
ase gene driven by TGF-b-responsive plasminogen activator inhibitor-1
promoter sequences (Abe et al., 1994), were seeded in 96-well plates
and allowed to adhere overnight. Serum-free medium supplemented
with recombinant human TGF-b for the generation of a standard
curve, naı¨ve glioma-conditioned medium for active TGF-b estimation
or heat-treated (80C, 5 min) conditioned medium for total TGF-b
estimation were added to the transfected mink lung epithelial cells,
which were harvested 18 h later. Luciferase activity was measured
using the luciferase assay system (Promega).
Reporter assay
Intracellular TGF-b signalling was assessed by reporter assays using the
pGL3-SBE4-Luc (Zawel et al., 1998) reporter plasmid kindly provided
by B. Vogelstein (Baltimore, MD). The pGL2-3TP-Luc construct con-
tains a synthetic promoter composed of a TGF-b-responsive plasmino-
gen activator inhibitor-1 promoter fragment inserted downstream of
three phorbol ester-responsive elements and was kindly provided by J.
Massague (New York, NY). The pGL3-TGF-b1-453-luc plasmid
includes the wild-type TGF-b1 promoter fragment 453/ + 1 fused
to the luciferase gene (Weigert et al., 2002). The pGL31065/ + 11
plasmid harbours nucleotides 1065 to + 11 of the human TGF-b1
promoter (Weigert et al., 2004). Both constructs were generous gifts
from C. Weigert (Tuebingen, Germany). Three reporter plasmids with
different fragments of the TGF-b2-promoter were kindly provided by
C. Knabbe (Stuttgart, Germany). The pGL3-TGF-b2-promoter con-
structs contain the following parts of the promoter: (1729/ + 64
wild-type), (778/ + 64 wild-type) and (531/ + 64 wild-type)
(Beisner et al., 2006). Dual luciferase/renilla assays were performed
with co-transfection of 150 ng of the respective reporter construct
and 20 ng of pRL-CMV. Luciferase activity was normalized to consti-
tutive renilla activity (pRL-CMV).
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Animal studies
Athymic CD1 nude mice were purchased from Charles River
Laboratories. Mice of 6–12 weeks of age were used in all experiments.
The experiments were approved by the local authorities. Before all
intracranial procedures, mice were anaesthetized by an intraperitoneal
3-component injection comprising fentanyl, midazolam and medeto-
midin. For intracranial implantation, the mice were placed in a stereo-
tactic fixation device (Stoelting) and a burr hole was drilled in the skull
2-mm lateral and 1-mm posterior to the bregma. The needle of a
Hamilton syringe was introduced to a depth of 3 mm. LN-308
glioma cells (105) in a volume of 2 ml PBS were injected into the
right striatum. Six weeks after tumour inoculation, cilengitide
(90 mg/kg) or PBS were injected on five consecutive days. Three
hours after the last injection, all mice were sacrificed and brain
cryosections were immediately prepared for haematoxylin and eosin
staining or for further analyses. pSmad2 expression was assessed by
immunofluorescence microscopy as described above. All pictures
were taken with a 63 oil immersion objective (1.4 numerical
aperture; Leica Microsystems). A CLSM Leica SP5 microscope (Leica
Microsystems) attached to a diode and a helium neon laser were used
to provide excitation at 405 nm and 561 nm wavelengths. The emitted
fluorescence light was detected via two adjustable photomultiplier
detectors. Three single images from different brain sections from one
animal were recorded and included in the quantification. The surface
detection function from Bitplane Imaris (Bitplane) was used to identify
all DAPI-positive areas as nucleus per picture and to exclude extra-
nuclear signals. The total fluorescence intensity of Cy3 in each nucleus
was determined and normalized to the nucleus size (fluorescent
intensity/mm2 nucleus area) to avoid false signals because of different
nucleus sizes. The total fluorescence intensity of three pictures of three
animals per group was averaged.
Statistics
Data are expressed as mean and standard deviation. The experiments
shown were repeated three times with similar results. Analysis of sig-
nificance was performed using the two-tailed Student’s t-test (Excel,
Microsoft) (*P5 0.05, **P5 0.01).
Results
Integrin expression in human gliomas
in vivo and in glioma-initiating cell
lines in vitro
Integrins vb3 and vb5 are expressed in tumour vasculature and
integrins vb6 and vb8 have been attributed to a role in TGF-b
activation (Munger et al., 1999; Mu et al., 2002; Cambier et al.,
2005; Alghisi and Ruegg, 2006). This prompted us to determine
the expression of these integrins by immunohistochemistry
on tissue microarray of gliomas of different WHO grades
of malignancy. In glioblastomas, no staining for vb6 was
found, whereas a rather homogeneous expression pattern was
observed for the other v integrins (Fig. 1A). The integrin expres-
sion in endothelial cells versus tumour cells proper was separately
analysed in gliomas of different WHO grades. No vb6 expression
was detected in any glioma either in tumour or endothelial
cells. In endothelial cells, the antibodies to pan-v revealed a
homogenous expression pattern in all gliomas. In contrast, the
expression of integrin vb3 was higher in glioblastoma tissue
than in grade II and III tumours, whereas vb5 levels were
higher in grade II tumours than in grade III and IV gliomas. No
staining was observed for vb8 in endothelial cells of any glioma
(Fig. 1B). Tumour cells within glioblastoma tissue displayed higher
v, vb5 and vb8 expression levels than in WHO grade II and III
tumours. The antibody to integrin vb3 revealed faint patterns of
expression, but also with the highest levels in grade IV gliomas
(Fig. 1C). The expression of integrins vb3 and vb5 in long-term
glioma cell lines has previously been characterized in our labora-
tory (Maurer et al., 2009). Here we confirmed expression of the
relevant integrins in LN-308 cells (Fig. 2A) and further demon-
strated the presence of these integrins on the surface of glioma-
initiating cell lines (Fig. 2B).
Integrin inhibition interferes with
Smad2 phosphorylation in human
glioblastoma cells
If integrin inhibition impaired TGF-b activation, a reduced phos-
phorylation of Smad2, a central effector of TGF-b signalling,
would be predicted to occur. Accordingly, LN-308 glioma cells
treated with antibodies specifically blocking different v integrins
exhibited reduced Smad2 phosphorylation after 48 h (Fig. 3A).
Similarly, we used small interfering RNA oligonucleotides to spe-
cifically silence the expression of single integrins in LN-308 glioma
cells. Compared with control transfectants, the cell surface expres-
sion of all integrins was strongly reduced (Supplementary Fig. 1A).
Integrin gene silencing was confirmed to be specific, e.g. b5 gene
silencing did not affect expression of the other integrins
(Supplementary Fig. 1B). Reduced pSmad2 levels were observed
relative to cells treated with scrambled control small interfering
RNA oligonucleotides (Fig. 3A). Further, Smad2 phosphorylation
in LN-308 cells declined as soon as 4 h after exposure to cilengi-
tide, a cyclic RGD pentapeptide with high affinity for integrins
vb3 and vb5 (Mas-Moruno et al., 2010) (Fig. 3A). The
glioma cell lines LN-18, U87MG, T98G and to a moderate
degree LNT-229 too showed reduced pSmad2 levels when treated
with cilengitide (Fig. 3A). This reduction in pSmad2 levels was
paralleled with an increase in total Smad2/3 levels, most promi-
nently in LNT-229 cells, and probably reflects a negative feedback
loop. The loss of pSmad2 induced by cilengitide was already
apparent at 1mM, near the IC50 for cilengitide-mediated inhibition
of vb3/vb5-dependent glioma cell attachment (Maurer et al.,
2009). The addition of exogenous TGF-b1 at 52 ng/ml restored
Smad 2 phosphorylation in LN-308 cells (Supplementary Fig. 2A),
but did not restore attachment. Still, we considered the possibility
that loss of pSmad2 resulted from detachment alone, and
observed that poly-HEMA-mediated detachment promoted a loss
of pSmad2 and an increase of total Smad2/3 (Supplementary Fig.
2B). Therefore, to assess whether the loss of pSmad2 is a specific
effect of cilengitide or rather a result of detachment, we examined
the attached and detached LN-308 cell fractions for pSmad2 in
response to cilengitide separately. Interestingly, Smad2 depho-
sphorylation was even more prominent in those LN-308 cells still
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Figure 1 Integrins are expressed in gliomas in vivo. (A) Paraffin-embedded glioblastoma sections were immunostained with rabbit
monoclonal antibodies to integrins pan-v, vb3, vb5, vb6 and vb8. Representative stainings are shown for each integrin. Scale
bars = 50 mm. (B and C) Expression levels for all integrins were quantified separately in endothelial cells (B) and tumour cells (C). The
respective mean scores for WHO grade II, III and IV glioma sections are shown. Significant differences between the three groups are
indicated by asterisks (*P4 0.05; **P40.01).
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attached to the cell culture flasks than in the detached fraction
floating in the media (Supplementary Fig. 2B). Thus interference
with Smad2 phosphorylation is likely to be a specific effect of
cilengitide on glioma cells and not simply a result of cell
detachment.
To confirm the assumption that interference with integrin sig-
nalling results in a suppression of the Smad2 pathway, we tran-
siently transfected LN-308 or LNT-229 cells with a reporter
construct containing four copies of the Smad-binding site (SBE4-
Luc) or the artificial TGF-b reporter plasmid 3TP-Luc. These con-
structs report TGF-b signalling, which was significantly reduced
when the cells were exposed to integrin-blocking antibodies, spe-
cific small interfering RNA oligonucleotides or cilengitide, but not
with their corresponding controls (Fig. 3B).
Inhibition of integrin activity decreases
TGF-b protein release by glioma cells
We next sought to clarify the mechanisms underlying reduced
pSmad2 levels and decreased TGF-b-dependent reporter activity
and assessed the effects of integrin inhibition on total TGF-b1 and
TGF-b2 levels in the cell culture media by ELISA. Exposure of LN-
308 glioma cells to integrin-blocking antibodies resulted in
decreased TGF-b1 and TGF-b2 protein levels in the cell culture
supernatant after 48 h. The strongest reduction in TGF-b protein
levels was observed in cells that had been exposed to the pan
integrin v antibody 17E6, closely followed by vb3 and vb5
inhibition (Fig. 4A). When using RNA interference to specifically
silence single integrins, a strong reduction of TGF-b1 and TGF-b2
protein was also observed. Cells with a knock-down of integrin v
displayed the most prominent decrease in TGF-b expression.
However, the expression levels of TGF-b were reduced by the
knock-down of each integrin chain investigated (Fig. 4B).
Additional experiments with a second set of small interfering
RNA oligonucleotides resulted in a specific knock-down of integ-
rins (Supplementary Fig. 3A) and a reduction of TGF-b levels
(Supplementary Fig. 3B). Finally, exposure of glioma cells to cilen-
gitide also resulted in decreased TGF-b1 (Fig. 4C), and more pro-
minently TGF-b2 levels (Fig. 4C) in all glioma cell lines tested.
Prominent reductions were noticed in LN-18, T98G and LN-308
Figure 2 Integrin expression in human glioma cell lines. (A and B) Integrin expression was determined by flow cytometry of LN-308 (A,
profiles) or glioma-initiating cell lines (B), expressed as specific fluorescence index (SFI) values.
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cells below 50% (Fig. 4C). Similarly, most glioma-initiating cell
lines responded to cilengitide with decreased TGF-b levels in the
cell culture medium (Fig. 4C).
If cilengitide was affecting the TGF-b pathway mainly by acting on
the activation of latent TGF-b, then there should be a difference
between the ratios of latent as opposed to active TGF-b between
control-treated and cilengitide-treated cells. Interestingly, at 1-mM
exposure for 24 h, cilengitide had significant effect on active, but not
total, levels of TGF-b, whereas both active and total TGF-b were
reduced at 10 mM (Fig. 4D), suggesting a dual mode of action of
integrin inhibition and TGF-b bioactivity.
Integrin targeting by blocking antibo-
dies, RNA interference or cilengitide
suppresses TGF-b expression on the
transcriptional level
Based on the observation of reduced TGF-b protein levels in the
supernatant, we asked whether integrin inhibition reduces TGF-b
expression mainly on the transcriptional level. LN-308 glioma cells
treated with antibodies specifically blocking different v integrins
displayed reduced TGF-b1 and -b2 messenger RNA expression
Figure 3 Integrin inhibition decreases Smad2 phosphorylation and TGF-b-induced reporter gene activity. (A) Whole cell protein lysates of
LN-308 glioma cells, cultured with specific antibodies to different integrins as indicated (top), or transiently transfected with small
interfering RNA oligonucleotides specific for one integrin or a control small interfering RNA (middle), were assessed for pSmad2 and total
Smad2/3 levels by immunoblot, using GAPDH as a loading control. In the bottom panel, LN-308, LN-18, U87MG, T98G or LNT-229 cells
were exposed to control peptide ( ) or cilengitide (10mM) as indicated and assessed for pSmad2 and total Smad2/3 levels. (B) LN-308 or
LNT-229 cells were exposed to blocking antibodies (top) or small interfering RNA oligonucleotides (middle) as in (A). In the bottom panel,
LN-308 or LNT-229 cells were exposed to the control peptide RAD (black bars), 2.5mM (light grey) or 10 mM (dark grey) cilengitide for
24 h. Intracellular TGF-b signalling was assessed by reporter assays using the pGL3-SBE4-Luc and pGl2-3TP-Luc constructs (*P50.05 and
**P50.01 compared with isotype control and scrambled small interfering RNA or RAD, respectively).
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Figure 4 Integrin inhibition suppresses TGF-b protein release. Supernatant from LN-308 glioma cells, exposed to integrin blocking or
isotype control antibodies (A) or small interfering RNA-mediated integrin gene silencing (B), were assessed for TGF-b1 and -b2 protein
levels by ELISA. (C) TGF-b1 (left) or TGF-b2 (right) protein levels in the cell culture supernatant were determined by ELISA after exposure
of glioma cells to 10 mM control peptide or cilengitide (Cil) for 48 h. Similar studies were performed using glioma-initiating cell lines
(bottom). (D) LN-308 or LNT-229 cells were exposed to control peptide (RAD) or cilengitide for 48 h as indicated and native or heat-
activated supernatants (SN) were assessed in an 18-h transfected mink lung epithelial cells assay for TGF-b bioactivity.
Integrin inhibition suppresses TGF-b signalling in glioblastoma Brain 2013: 136; 564–576 | 571
levels as determined by real-time PCR (Fig. 5A). Integrin gene
silencing using RNA interference also resulted in decreased TGF-
b1 and TGF-b2 messenger RNA levels with strongest effects
observed after silencing of integrin v. Finally, we investigated
the effects of cilengitide on TGF-b transcripts. Time course ana-
lyses of messenger RNA levels in LN-308 cells revealed a reduction
in TGF-b1 and TGF-b2 messenger RNA (by 450%) within 24 h of
exposure to cilengitide, suggesting a transcriptional repression of
the TGF-b genes by cilengitide (Fig. 5A). Yet, only minor changes
at 4 and 12 h were observed, especially for TGF-b1, a time point
where pSmad levels were already reduced (Fig. 3A).
To confirm the findings obtained by real-time PCR, we exam-
ined the effects of all three approaches of integrin inhibition on
the TGF-b1 and TGF-b2 promoter. Both reporter plasmid con-
structs are sensitive to changes in the transcription of the respec-
tive TGF-b gene. Consistent with the messenger RNA data,
targeting integrins with blocking antibodies or small interfering
RNA oligonucleotides also induced a reduction of relative lucifer-
ase activity in LN-308 and LNT-229 glioma cells (Fig. 5B). A
reduction of luciferase activity was also observed when the cells
were exposed to cilengitide. Here we examined two constructs of
different lengths of the TGF-b1 promoter and three constructs of
different lengths of the TGF-b2 upstream promoter. For both the
TGF-b1 and -b2 promoters, a similar reduction in expression levels
was noticed independently of the size of the promotor fragment
(531–1729 bp upstream).
Cilengitide induces Smad2 depho-
sphorylation in vivo
Compared with blocking antibodies and small interfering RNA oli-
gonucleotides, cilengitide is the clinically most advanced approach
to target integrins in glioblastoma. Therefore, we aimed to deter-
mine the effect of cilengitide on TGF-b signalling in vivo. As a
prerequisite, we examined Smad2 phosphorylation in LN-308
glioma cells by immunofluorescence microscopy in vitro and
observed reduced pSmad2 levels after exposure to cilengitide,
using SD-208 as a positive control (Fig. 6A). For in vivo analyses,
glioma-bearing nude mice were treated with cilengitide or PBS for
five consecutive days. Histopathological analyses demonstrated
the presence of tumours in all mice. We also confirmed the
expression of the target integrins in vivo, which was unchanged
after 5 days of cilengitide treatment (Fig. 6B). Immunofluorescent
stainings displayed heterogeneous effects of cilengitide on Smad2
phosphorylation in the cilengitide-treated mice. In some animals,
there was a distinct reduction of pSmad2 levels, whereas other
mice appeared not to respond to cilengitide (Fig. 6C). A compre-
hensive quantification of pSmad2 staining revealed a non-signifi-
cant trend towards reduced Smad2 phosphorylation in the cohort
of cilengitide-treated mice (Fig. 6D).
Discussion
Glioblastoma remains a major challenge in the field of clinical
neuro-oncology. The addition of alkylating chemotherapy to
radiotherapy has increased the median survival of patients to
15 months in clinical trials (Stupp et al., 2005). Hope for further
improvement centres on several novel therapeutic agents that are
currently being investigated within clinical trials, notably antiangio-
genic agents. The switch of a tumour to an angiogenic phenotype
is believed to be one essential step in the multistage process
towards malignancy (Hanahan and Folkman, 1996). The tumour
vasculature is therefore now seen as a promising therapeutic
target in oncology. Antiangiogenic agents in advanced clinical
development for glioblastoma include the vascular endothelial
growth factor antibody bevazicumab (Vredenburgh et al., 2007),
the vascular endothelial growth factor receptor antagonist cedir-
anib (Batchelor et al., 2010) and the vb3 and vb5 integrin
antagonist, cilengitide (Reardon et al., 2008; Stupp et al., 2010).
Despite advanced clinical evaluation, the mechanisms that mediate
clinically beneficial effects of cilengitide in particular, and integrin
inhibition in general, remain unknown. Both endothelial and
tumour cells might be target cells for such approaches because
both express integrins in glioblastoma, albeit in a heterogeneous
manner: vb3 was expressed typically at high levels in endothelial
cells, which were vb8-negative, and tumour cells within glioblas-
tomas expressed all three target integrins, but preferentially vb5
and vb8 (Fig. 1).
TGF-b has been considered as a promising therapeutic target
because of its multiple effects contributing to some of the hall-
marks of malignant gliomas such as invasiveness or poor immu-
nogenicity (Wick et al., 2006). Its regulation by integrins has not
been studied in glioblastoma. Because a biologically relevant
downregulation of TGF-b should reduce Smad2 phosphorylation,
we first explored this pathway in several glioma cell lines.
Targeting single integrin complexes with blocking antibodies or
small interfering RNA-mediated integrin gene silencing resulted
in a downregulation of Smad2 phosphorylation in LN-308
glioma cells (Fig. 3A). Owing to the lack of a commercially avail-
able antibody with blocking properties against vb8, we could
target this integrin only by RNA interference. When LN-308 cells
were exposed to cilengitide, a downregulation of Smad2 phos-
phorylation was observed as soon as 4 h after addition of the
compound. This effect peaked at 48 h, and was also seen in
other glioma cell lines. As previously reported, some glioma cell
lines detach in the presence of cilengitide (Maurer et al., 2009),
but the effects of cilengitide on Smad2 phosphorylation were
independent of detachment. Rather as we show here, they reflect
a specific integrin blockade by cilengitide. Smad2 dephosphoryla-
tion was more pronounced in cells that remained attached in
response to cilengitide compared with detached cells, confirming
that Smad2 dephosphorylation is not mediated solely by cell
detachment (Supplementary Fig. 2B). Exogenous recombinant
TGF-b counteracted the effect of cilengitide on Smad2 phosphor-
ylation, suggesting that cilengitide does not directly block TGF-b
receptor-mediated signalling, indeed, as yet few off-target effects
have been identified for cilengitide (Supplementary Fig. 2A).
Consistent with these findings, the activity of two reporter con-
structs reflecting Smad2/TGF-b signalling was significantly reduced
when the cells were exposed to integrin-blocking antibodies,
specific small interfering RNA oligonucleotides, cilengitide, but
not with the appropriate controls (Fig. 3B). Next we asked
whether the effects of integrin inhibition on pSmad2 levels and
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Figure 5 Integrin inhibition suppresses TGF-b gene transcription. (A) LN-308 glioma cells were cultured with integrin blocking or isotype
control antibodies as indicated. TGF-b1 and -b2 messenger RNA expression levels were determined by real-time PCR after 48 h and
normalized to isotype-treated cells (top). LN-308 glioma cells were transiently transfected with small interfering RNA oligonucleotides
specific for one integrin or a control small interfering RNA and TGF-b1 and -b2 messenger RNA levels were determined (middle). TGF-b1 or
-b2 messenger RNA expression were assessed by real-time PCR after exposure to 10 mM cilengitide (Cil) at the indicated time points and
compared with cells that had been exposed to control peptide (bottom). (B) Glioma cells were transfected with constructs of different
lengths of the TGF-b1 or TGF-b2 promoter and treated as in (A) (*P50.05 and **P50.01 compared with isotype control and scrambled
small interfering RNA or the control peptide RAD, respectively).
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TGF-b-dependent reporter activity resulted from a loss of TGF-b
protein in the supernatant. Indeed, integrin inhibition with all three
approaches reduced TGF-b protein levels in the glioma cell culture
supernatant (Fig. 4A–C).
Previous findings suggested a link between integrin signalling and
post-transcriptional processing of TGF-b (Munger et al., 1999;
Mu et al., 2002). However, glioma cell supernatants from cilengi-
tide-treated cells showed reduced TGF-b bioavailability, both active
and total TGF-b, and not only of active TGF-b, suggesting that inter-
ference with activation is not the sole activity of cilengitide. However,
Fig. 4D indicates that specifically lower concentrations may exert an
effect on TGF-b activity in the absence of effects on total TGF-b.
Figure 6 Effects of cilengitide on Smad2 phosphorylation in LN-308 gliomas in vivo. (A) LN-308 glioma cells were exposed to RAD or
cilengitide (10 mM), TGF-b2 (10 ng/ml) or SD-208 (1 mM) and assessed for pSmad2 expression after 48 h by immunofluorescence
microscopy (original magnification 40). (B) LN-308 cells were inoculated intracerebrally in athymic CD1 nude mice. The animals were
treated intraperitoneally with cilengitide (90 mg/g body weight) or PBS for 5 days starting 3 weeks after tumour cell inoculation.
Subsequently, the animals’ brains were removed, shock-frozen and integrin expression was assessed by immunohistochemistry as
indicated (original magnification 10 for haematoxylin and eosin and 40 for pSmad2). (C) pSmad2 levels were assessed by immu-
nohistochemistry (C) and quantified (D).
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Indeed, we found that TGF-b1 and -b2 messenger RNA levels
declined after integrin inhibition with blocking antibodies or RNA
interference or exposure of glioma cells to cilengitide (Fig. 5).
Additionally, TGF-b gene promoters show reduced activity on integ-
rin inhibition with all three approaches. For both TGF-b1 and TGF-b2,
similar results were obtained independently from the length of the
promoter construct (between 1729–453 bp), indicating that any
functionally relevant part of the promoter is even closer to the
gene’s coding sequence. We also considered the possibility that
the cilengitide effects on TGF-b transcription were a result of
decreased levels of TGF-b. This interpretation would require that
TGF-b controls its own transcription in the experimental system
used here. However, previous experiments had not indicated a
major contribution of autocrine TGF-b loops to the total TGF-b activ-
ity in glioma cell line studies (Leitlein et al., 2001; Uhl et al., 2004).
The possible clinical importance of our findings was supported
by the observation that Smad2 phosphorylation was attenuated in
some LN-308 glioma-bearing nude mice treated with cilengitide,
identifying the compound as a weak integrin antagonist when
pSmad2 phosphorylation is defined as the biological endpoint.
The heterogeneous findings here may reflect the clinical situation
where cilengitide monotherapy probably neither provides a survi-
val benefit in glioma patients nor causes significant toxicity.
A minority of recurrent glioblastoma patients showed durable
responses even to cilengitide alone (Reardon et al., 2008), but a
biomarker to identify such patients has not been established.
Absence of target integrin expression would be expected to pre-
dict failure of clinical benefit from integrin inhibitors and may in
the future be assessed non-invasively by Positron emission tomo-
graphy (PET) (Schnell et al., 2009). In our animal model, there was
little response to cilengitide at the level of pSmad2 levels although
the target integrins were expressed (Fig. 6), indicating that there
are either intracellular mechanisms of resistance operating in vivo
or that the intrinsic activity of cilengitide is too low, at the dosing
schedule used here, or both. However, our findings highlight integ-
rin inhibition as a promising therapeutic approach in glioblastoma
and demonstrate that the best way to interfere with integrin sig-
nalling still needs to be defined. In summary, the results of this
study reveal suppression of the TGF-b pathway as a novel mechan-
ism by which integrin inhibition may be exploited in human
patients with TGF-b-dependent tumours such as glioblastoma.
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